| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 25mg |
|
||
| 50mg |
|
||
| 100mg | |||
| Other Sizes |
Purity: ≥98%
| Targets |
SI113 targets SGK1 (serum- and glucocorticoid-inducible kinase 1), a serine/threonine protein kinase that regulates ion channel activity, cell survival, proliferation, and apoptosis. SGK1 is involved in several oncogenic signaling cascades and is overexpressed in various cancers. SI113 is a potent and selective inhibitor of SGK1 kinase activity.
|
|---|---|
| ln Vitro |
In GIN8, GIN28, and GCE28 GBM cells, the IC50 values of SI-113 are 10.5, 14.4, and 10.7 μM, respectively[1]. In all GBM cell lines, SI-113 significantly increases the activation of caspase-3/7 [1]. SI-113 inhibits the development of human glioblastoma multiforme cells by inducing autophagy and working in concert with quinacrine [2].
SI113 inhibits SGK1 kinase activity with an IC50 of 600 nM. In cancer cells, SI113 induces autophagy, apoptosis, and ER stress. These effects contribute to its antiproliferative activity and its ability to counteract cancer cell proliferation. The compound has shown activity in various cancer cell lines. |
| ln Vivo |
In vivo activity of SI113 has been reported in preclinical models of cancer. As an SGK1 inhibitor, SI113 has shown efficacy in reducing tumor growth in xenograft models. The compound's ability to induce autophagy and apoptosis contributes to its antitumor effects. Further studies are needed to fully characterize its in vivo pharmacokinetic and pharmacodynamic profile.
|
| Enzyme Assay |
SGK1 kinase activity is assessed using in vitro kinase assays with purified recombinant SGK1 protein and a suitable peptide substrate (e.g., a peptide derived from NEDD4-2 or other SGK1 substrates). The assay measures the incorporation of [γ-³²P]-ATP into the substrate or uses a coupled enzymatic assay with ATP depletion detection. SI113 is incubated at various concentrations, and IC50 values are calculated from dose-response curves. Selectivity profiling against a panel of related kinases (e.g., AKT, PKC, ROCK) is performed to confirm selectivity.
|
| Cell Assay |
Cellular activity is evaluated in cancer cell lines that express SGK1. Cells are treated with SI113 at various concentrations for 24-72 hours. Apoptosis is assessed using Annexin V/PI staining or caspase activity assays. Autophagy is evaluated by measuring LC3-II conversion or GFP-LC3 puncta formation. ER stress markers (e.g., CHOP, BiP) are measured by Western blot. Cell proliferation and viability are measured using MTT, XTT, or CellTiter-Glo assays.
|
| Animal Protocol |
SI113 is typically administered orally or intraperitoneally in murine xenograft models. Tumor-bearing mice are treated with SI113 at various doses (e.g., 10-50 mg/kg) on a daily or every-other-day schedule. Tumor volumes are measured twice weekly, and body weight is monitored. At the end of the study, tumors are harvested for analysis of SGK1 inhibition (e.g., phosphorylation of SGK1 substrates), apoptosis markers, and autophagy markers.
|
| ADME/Pharmacokinetics |
SI113 has a molecular weight of 400.49 and molecular formula C23H24N6O. It is soluble in DMSO. The compound is stable when stored at -20°C or below. SI113 is a small-molecule SGK1 inhibitor with drug-like properties suitable for preclinical development. Further pharmacokinetic studies are needed to determine oral bioavailability, half-life, and tissue distribution.
|
| Toxicity/Toxicokinetics |
Preclinical toxicity studies of SI113 have not been extensively reported. As an SGK1 inhibitor, mechanism-based toxicities may include effects on renal function (due to SGK1's role in sodium homeostasis) and cell survival pathways. In vitro studies have shown that SI113 induces autophagy, apoptosis, and ER stress in cancer cells, which are desirable for anticancer activity but could contribute to off-target toxicity in normal cells. Further toxicological characterization is needed.
|
| References |
|
| Additional Infomation |
SI113 (CAS#: 1392816-46-4) is a potent and selective inhibitor of SGK1 with an IC50 of 600 nM. It induces autophagy, apoptosis, and ER stress in cancer cells and counteracts cancer cell proliferation. SI113 is being investigated as a potential therapeutic agent for cancers driven by SGK1 overexpression. The compound is intended for research use only and is not for therapeutic use. Its mechanism of action involves inhibition of SGK1 kinase activity, leading to reduced cell survival and proliferation.
|
| Molecular Formula |
C23H24N6O
|
|---|---|
| Molecular Weight |
400.476263999939
|
| Exact Mass |
400.201
|
| CAS # |
1392816-46-4
|
| Related CAS # |
1392816-46-4;1283727-37-6;
|
| PubChem CID |
142416508
|
| Appearance |
White to off-white solid powder
|
| LogP |
4.2
|
| Hydrogen Bond Donor Count |
3
|
| Hydrogen Bond Acceptor Count |
6
|
| Rotatable Bond Count |
9
|
| Heavy Atom Count |
30
|
| Complexity |
520
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
OCCNC1=NC2=C(C=NN2/C=C\C2C=CC=CC=2)C(=N1)NCCC1C=CC=CC=1
|
| InChi Key |
LAOYAWHHLUVMFT-QINSGFPZSA-N
|
| InChi Code |
InChI=1S/C23H24N6O/c30-16-14-25-23-27-21(24-13-11-18-7-3-1-4-8-18)20-17-26-29(22(20)28-23)15-12-19-9-5-2-6-10-19/h1-10,12,15,17,30H,11,13-14,16H2,(H2,24,25,27,28)/b15-12-
|
| Chemical Name |
(Z)-2-((4-(Phenethylamino)-1-styryl-1H-pyrazolo[3,4-d]pyrimidin-6-yl)amino)ethan-1-ol
|
| Synonyms |
SI113 SI-113 SI 113
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~250 mg/mL (~624.25 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.4970 mL | 12.4850 mL | 24.9700 mL | |
| 5 mM | 0.4994 mL | 2.4970 mL | 4.9940 mL | |
| 10 mM | 0.2497 mL | 1.2485 mL | 2.4970 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
COA